Facebook
Twitter
LinkedIn
Forward
Obesity is a heterogeneous, complex, chronic, and progressive disease. It is essential that clinicians recognize that a patient’s disease response to treatment can vary significantly.
|
The rise in the use of glucagon-like peptide 1 receptor agonists (GLP-1RA) for weight loss has generated significant interest due to their efficacy in reducing body weight.
|
Obesity causes or contributes to over 200 diseases including at least 13 types of cancer. People with obesity are also at an elevated risk of death from cancer.
|
The transition through perimenopause and menopause involves hormonal changes that affect weight, body composition, and metabolism.
|
In this session we will highlight key elements in gathering a history, chart documentation, and establishing critical workflows to enhance patient care while improving the prior authorization proce
|
This session will include a focused overview of lipedema, bringing together unique perspectives from an occupational therapist (CLT), patient/advocate, and obesity medicine physician, combining dec
|
Obesity is associated with cardiovascular disease.
|
This session will explore the intricate relationship between hormones and obesity in women across different life stages.
|
Year in Review presentation with outgoing and incoming OMA PresidentCME/CE Expiration Date: 4/27/28
|
The core of obesity treatment are lifestyle factors including physical activity.
|